文献速递肾移植

基于模型贝叶斯预测的肾移植受者个体化他克莫司给药随机对照试验

A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction.
PubMed 文献 · Kidney Int · 2023-06-28

该前瞻性两臂随机临床试验纳入90例肾移植受者,比较基于群体药代动力学模型(含药物遗传学、年龄、红细胞压积)的贝叶斯预测给药与按说明书体重给药对他克莫司谷浓度达标的影响。PPK组54.8%患者达标,对照组20.8%,PPK组达标更早(5天 vs 10天)、剂量调整更少、个体内变异更低,但临床结局无显著差异。

要点

  • PPK组54.8%患者达到他克莫司目标谷浓度,对照组为20.8%。
  • PPK组达标时间5天,对照组10天。
  • PPK组90天内剂量调整次数显著少于对照组,个体内变异更低。

核心结论

  • 基于PPK模型的贝叶斯预测他克莫司给药在起始处方方面显著优于按体重说明书给药,可能优化移植后早期他克莫司治疗。

研究设计与样本

  • 前瞻性两臂随机临床试验,纳入90例肾移植受者,随机分为对照组(按说明书体重调整他克莫司剂量)和PPK组(使用贝叶斯预测模型NONMEM调整剂量以达到目标谷浓度6-10 ng/ml)。

主要发现

  • PPK组54.8%患者达到治疗目标,对照组20.8%,满足预设30%优效界值。
  • PPK组患者个体内变异显著低于对照组。
  • PPK组达到他克莫司目标谷浓度时间5天 vs 对照组10天。
  • PPK组肾移植后90天内他克莫司剂量调整次数显著少于对照组。
  • 两组临床结局无统计学显著差异。

关键数值与推荐

  • 目标他克莫司谷浓度(Co)为6-10 ng/ml,在首次稳态后评估(主要终点)。
  • PPK组54.8% vs 对照组20.8%达到治疗目标,满足预设30%优效界值。

临床怎么用

  • PPK模型包含药物遗传学(CYP3A4/CYP3A5簇)、年龄和红细胞压积,可用于肾移植受者他克莫司起始和后续剂量调整。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For three decades, tacrolimus (Tac) dose adjustment in clinical practice has been calculated empirically according to the manufacturer's labeling based on a patient's body weight. Here, we developed and validated a Population pharmacokinetic (PPK) model including pharmacogenetics (cluster CYP3A4/CYP3A5), age, and hematocrit. Our study aimed to assess the clinical applicability of this PPK model in the achievement of Tac Co (therapeutic trough Tac concentration) compared to the manufacturer's labelling dosage. A prospective two-arm, randomized, clinical trial was conducted to determine Tac starting and subsequent dose adjustments in 90 kidney transplant recipients. Patients were randomized to a control group with Tac adjustment according to the manufacturer's labeling or the PPK group adjusted to reach target Co (6-10 ng/ml) after the first steady state (primary endpoint) using a Bayesian prediction model (NONMEM). A significantly higher percentage of patients from the PPK group (54.8%) compared with the control group (20.8%) achieved the therapeutic target fulfilling 30% of the established superiority margin defined. Patients receiving PPK showed significantly less intra-patient variability compared to the control group, reached the Tac Co target sooner (5 days vs 10 days), and required significantly fewer Tac dose modifications compared to the control group within 90 days following kidney transplant. No statistically significant differences occurred in clinical outcomes. Thus, PPK-based Tac dosing offers significant superiority for starting Tac prescription over classical labeling-based dosing according to the body weight, which may optimize Tac-based therapy in the first days following transplantation.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Lloberas N, Grinyó JM, Colom H, et al. A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction. Kidney Int. 2023. PMID: 37391040. doi:10.1016/j.kint.2023.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。